Vaxart (NASDAQ:VXRT) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Vaxart (NASDAQ:VXRT - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05, Zacks reports. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The company had revenue of $15.19 million for the quarter, compared to analyst estimates of $15.68 million.

Vaxart Stock Performance

VXRT stock traded down $0.00 during midday trading on Monday, hitting $0.51. 1,497,135 shares of the company's stock were exchanged, compared to its average volume of 2,375,633. Vaxart has a one year low of $0.45 and a one year high of $1.41. The stock's fifty day moving average price is $0.65 and its 200-day moving average price is $0.71. The company has a market cap of $116.61 million, a PE ratio of -1.25 and a beta of 1.69.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.